doxorubicin

Open Access
Effects of Azelastine on Glioblastoma Cells
YUKI UEMICHI, SEINA YASUDA, MIYUKI MABUCHI, SHUHEI NAKAO, SHUJI NAGANO and TADASHI SHIMIZU

Anticancer Research July 2025, 45 (7) 2763-2771; DOI: https://doi.org/10.21873/anticanres.17645
You have access
High Antitumor Effects and Reduced Side Effects of Doxorubicin Prodrug Active Only Under Hypoxic Conditions
KOKI YOSHIOKA, TAISUKE FURUTA, TOMOHIKO SAKUDA, AKIHIRO ODA, YUTAKA IKEDA, SHIGERU MIYAKI, YUKIO NAGASAKI and NOBUO ADACHI

Anticancer Research July 2025, 45 (7) 2905-2916; DOI: https://doi.org/10.21873/anticanres.17658
You have access
In Vitro Evaluation of the Dual Pharmacological Action of Vitamin D₃ as Cardio-protectant and Anti-cancer Agent
YESENIA L. FRANCO, HARDIK MODY and SIHEM AIT-OUDHIA

Anticancer Research June 2025, 45 (6) 2351-2363; DOI: https://doi.org/10.21873/anticanres.17608
Open Access
Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma
SEI MORINAGA, QINGHONG HAN, KOHEI MIZUTA, BYUNG MO KANG, MOTOKAZU SATO, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA and ROBERT M. HOFFMAN

Anticancer Research August 2024, 44 (8) 3261-3268; DOI: https://doi.org/10.21873/anticanres.17144
You have access
PEMF Potentiates Doxorubicin-induced Late G₂ Arrest in MDA-MB-231 Breast Cancer Cells
SUNG-HUN WOO, BYUNG CHUL JUNG, JUN-YOUNG KIM, YONG-HEUM LEE and YOON SUK KIM

Anticancer Research July 2024, 44 (7) 2837-2846; DOI: https://doi.org/10.21873/anticanres.17096
You have access
Mesna, Doxorubicin, Ifosfamide and Dacarbazine (MAID) Combination Chemotherapy for Retroperitoneal Sarcoma: A Single-center Experience
YUDAI ISHIYAMA, TORU INAKAWA, MAKI YOSHINO, KOICHI NISHIMURA, TOSHIHIDE HORIUCHI, HIROKI ISHIHARA, DAISUKE TOKI and TSUNENORI KONDO

Anticancer Research July 2024, 44 (7) 3213-3220; DOI: https://doi.org/10.21873/anticanres.17137
You have access
Doxorubicin as Risk Factor for Fascial Dehiscence After CRS-HIPEC for Peritoneal Metastases
ELISA PIZZOLATO, CAROLA CENZI, MARCO TONELLO, PIERLUIGI PILATI and ANTONIO SOMMARIVA

Anticancer Research April 2024, 44 (4) 1553-1557; DOI: https://doi.org/10.21873/anticanres.16952
You have access
Terpyridine Functionalized Cyclodextrin Nanoparticles as Carriers for Doxorubicin: Analysis of In Vitro Antiproliferative Activity
MAURIZIO VIALE, NADIA BERTOLA, ROBERTA PANEBIANCO and GRAZIELLA VECCHIO

Anticancer Research December 2023, 43 (12) 5409-5414; DOI: https://doi.org/10.21873/anticanres.16744
Open Access
Antitumor Activity of Symmetrical Selenoesters in Doxorubicin Resistant Breast Cancer
BALINT RACZ, ERZSEBET KRISTOF, ANNAMARIA KINCSES, ENRIQUE DOMINGUEZ-ALVAREZ and GABRIELLA SPENGLER

Anticancer Research November 2023, 43 (11) 4865-4872; DOI: https://doi.org/10.21873/anticanres.16683
Open Access
Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction
YUTARO KUBOTA, QINGHONG HAN, NORIYUKI MASAKI, CHIHIRO HOZUMI, KAZUYUKI HAMADA, YUSUKE AOKI, KOYA OBARA, TAKUYA TSUNODA and ROBERT M. HOFFMAN

Anticancer Research December 2022, 42 (12) 5819-5823; DOI: https://doi.org/10.21873/anticanres.16089

Main menu

User menu

Search

doxorubicin

Pages